Standout Papers

Management of Hyperglycemia in Ty... 2003 2026 2010 2018 2.6k
  1. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018)
    Melanie J. Davies, David A. D’Alessio et al. Diabetes Care
  2. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018)
    Melanie J. Davies, David A. D’Alessio et al. Diabetologia
  3. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019)
    John B. Buse, Deborah J. Wexler et al. Diabetes Care
  4. A Randomized Trial Comparing a Very Low Carbohydrate Diet and a Calorie-Restricted Low Fat Diet on Body Weight and Cardiovascular Risk Factors in Healthy Women (2003)
    Bonnie J. Brehm, Randy J. Seeley et al. The Journal of Clinical Endocrinology & Metabolism
  5. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (2018)
    Tamer Coşkun, Kyle W. Sloop et al. Molecular Metabolism
  6. Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease (2015)
    Darleen A. Sandoval, David A. D’Alessio Physiological Reviews
  7. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019)
    John B. Buse, Deborah J. Wexler et al. Diabetologia
  8. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (2020)
    Francis S. Willard, Jonathan D. Douros et al. JCI Insight
  9. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (2022)
    Shweta Urva, Tamer Coşkun et al. The Lancet
  10. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal
  11. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets (2023)
    Kimberley El, Jonathan D. Douros et al. Nature Metabolism

Immediate Impact

5 by Nobel laureates 13 from Science/Nature 146 standout
Sub-graph 1 of 14

Citing Papers

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
Obesity in adults
2024 Standout
87 intermediate papers

Works of David A. D’Alessio being referenced

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
2023 Standout
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
2018 Standout
and 44 more

Author Peers

Author Last Decade Papers Cites
David A. D’Alessio 12394 8092 7071 253 22.6k
Fiona M. Gribble 8419 8462 6000 276 24.3k
Frank Reimann 7713 7106 5730 265 21.4k
Josephine M. Egan 7204 4755 5489 240 18.7k
Sten Madsbad 16568 11452 6891 537 26.7k
Daniel Porte 8280 6379 8945 185 26.6k
Robert S. Sherwin 9959 5166 5235 206 20.8k
Richard E. Pratley 16147 6320 9836 392 34.6k
John E. Gerich 15124 8819 7417 339 25.9k
Carel W. le Roux 6618 10170 10984 501 22.2k
Bo Åhrén 15941 12468 7467 717 32.4k

All Works

Loading papers...

Rankless by CCL
2026